StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.02−0.08 (-1.13%)

Close on Nov 17, 2026Market cap $254.77MP/E –Yield –

Evommune r&d expenses

Research and development expenses are spending on new products and technology.

Evommune's R&D Expenses for the twelve months ending Sep 30, 2026 was $88.69M, up 24.1% year over year. For fiscal 2025 it was $74.04M, up 15.3% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$74.04M+15.3%
FY2024Dec 31, 2024$64.24M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$24.55M+25.0%
Q2 FY2026Jun 30, 2026$26.41M+34.5%
Q1 FY2026Mar 31, 2026$17.32M+20.6%
Q4 FY2025Dec 31, 2025$20.40M+14.4%
Q3 FY2025Sep 30, 2025$19.64M+47.8%
Q2 FY2025Jun 30, 2025$19.64M–
Q1 FY2025Mar 31, 2025$14.36M–
Q4 FY2024Dec 31, 2024$17.83M–
Q3 FY2024Sep 30, 2024$13.29M–

More Evommune figures

See a number that looks wrong?